Current status of nonantibiotic and adjunct therapies for clostridium difficile infection

Current Infectious Disease Reports

Volumn 13, Issue 1, 2011, Pages 21-27

  Suwantarat, Nuntra ^a   Bobak, David A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Clostridium difficile infection; Nonantibiotic treatment

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; FUSIDIC ACID; GASTROINTESTINAL AGENT; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; SYNSORB 90; TEICOPLANIN; TINIDAZOLE; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIOPHAGE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; FECES MICROFLORA; HOSPITAL INFECTION; HUMAN; ILEOSTOMY; LACTOBACILLUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES; TOTAL COLON RESECTION; TREATMENT OUTCOME;

EID: 79551522234     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0155-7     Document Type: Article

References (78)

1. JG Bartlett 2008 Historical perspectives on studies of Clostridium difficile and C. difficile infection Clin Infect Dis 46 Suppl 1 S4 11 10.1086/521865 18177220 (Pubitemid 351323660)
2. DN Gerding 2009 Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 33 Suppl 1 S2 8 1:CAS:528: DC%2BD1MXjsFWlu7Y%3D 10.1016/S0924-8579(09)70008-1 19303564
3. HL DuPont K Garey JP Caeiro ZD Jiang 2008 New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control Curr Opin Infect Dis 21 500 7 10.1097/QCO.0b013e32830f9397 18725800
4. M Rupnik MH Wilcox DN Gerding 2009 Clostridium difficile infection: new developments in epidemiology and pathogenesis Nat Rev Microbiol 7 526 36 1:CAS:528:DC%2BD1MXntlGnsL0%3D 10.1038/nrmicro2164 19528959
5. DA Bobak 2008 The molecular pathogenesis of Clostridium difficile-associated disease Curr Infect Dis Rep 10 111 5 10.1007/s11908-008- 0020-0 18462584
6. H Genth SC Dreger J Huelsenbeck I Just 2008 Clostridium difficile toxins: more than mere inhibitors of Rho proteins Int J Biochem Cell Biol 40 592 7 1:CAS:528:DC%2BD1cXivVOmtb8%3D 10.1016/j.biocel.2007.12.014 18289919
7. SH Cohen DN Gerding S Johnson, et al. 2010 Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect Control Hosp Epidemiol 31 431 455 10.1086/651706 20307191
8. Y Belyi K Aktories 2010 Bacterial toxin and effector glycosyltransferases Biochim Biophys Acta 1800 134 43 1:CAS:528:DC%2BC3cXotVSqsA%3D%3D 19647041 This paper reviews the current knowledge regarding the structure and function of glycosyltransferases, including C. difficile toxins
9. RN Pruitt MG Chambers KK Ng, et al. 2010 Structural organization of the functional domains of Clostridium difficile toxins A and B Proc Natl Acad Sci USA 107 13467 72 1:CAS:528:DC%2BC3cXht1GrurbL 10.1073/pnas.1002199107 20624955
10. T Giesemann M Egerer T Jank K Aktories 2008 Processing of Clostridium difficile toxins J Med Microbiol 57 690 6 1:CAS:528:DC%2BD1cXosVGitL4%3D 10.1099/jmm.0.47742-0 18480324 This paper reviews current information regarding the intracellular processing and activation of C. difficile toxins (Pubitemid 351842059)
11. D Lyras JR O'Connor PM Howarth, et al. 2009 Toxin B is essential for virulence of Clostridium difficile Nature 458 1176 1179 1:CAS:528: DC%2BD1MXisVOrtLg%3D 10.1038/nature07822 19252482
12. SA Kuehne ST Cartman JT Heap, et al. 2010 The role of toxin A and toxin B in Clostridium difficile infection Nature 467 711 3 1:CAS:528: DC%2BC3cXhtFGntL%2FO 10.1038/nature09397 20844489 The gene knockout study in the hamster model of CDI demonstrated that either one, or both, of C. difficile toxins could demonstrate cytotoxicity in vitro and virulence in vivo
13. JG Bartlett 2008 The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection Clin Infect Dis 46 1489 92 1:CAS:528:DC%2BD1cXmvVSis78%3D 10.1086/587654 18419480 (Pubitemid 351706727)
14. JG Bartlett 2009 New antimicrobial agents for patients with Clostridium difficile infections Curr Infect Dis Rep 11 21 28 10.1007/s11908-009-0004-8 19094821
15. D Shah MD Dang R Hasbun, et al. 2010 Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance Expert Rev Anti Infect Ther 8 555 64 1:CAS:528:DC%2BC3cXlvVWltrg%3D 10.1586/eri.10.28 20455684
16. I Thompson 2008 Clostridium difficile-associated disease: update and focus on non-antibiotic strategies Age Ageing 37 14 8 10.1093/ageing/afm159 18033775 (Pubitemid 351146970)
17. P Hookman JS Barkin 2009 Clostridium difficile associated infection, diarrhea and colitis World J Gastroenterol 15 1554 80 10.3748/wjg.15.1554 19340897
18. HL Koo KW Garey HL Dupont 2010 Future novel therapeutic agents for Clostridium difficile infection Expert Opin Investig Drugs 19 825 36 1:CAS:528:DC%2BC3cXnt1aqt7w%3D 10.1517/13543784.2010.495386 20521993
19. I Sekirov SL Russell LC Antunes BB Finlay, et al. 2010 Gut microbiota in health and disease Physiol Rev 90 859 904 1:CAS:528:DC%2BC3cXhtVyku7rM 10.1152/physrev.00045.2009 20664075
20. Rea MC, Dobson A, O'Sullivan O,, et al. Microbes and Health Sackler Colloquium: Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2010, [epub ahead of print] doi: 10.1073/pnas.1001224107.
21. JY Chang DA Antonopoulos A Kalra, et al. 2008 Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea J Infect Dis 197 435 8 10.1086/525047 18199029 (Pubitemid 351263426)
22. M Pham DA Lemberg AS Day 2008 Probiotics: sorting the evidence from the myths Med J Aust 188 304 8 18312197
23. EM Quigley 2010 Prebiotics and probiotics; modifying and mining the microbiota Pharmacol Res 61 213 8 10.1016/j.phrs.2010.01.004 20080184
24. NT Williams 2010 Probiotics Am J Health Syst Pharm 67 449 58 1:CAS:528:DC%2BC3cXkvVOnu74%3D 10.2146/ajhp090168 20208051
25. Allen SJ, Okoko B, Martinez E, et al: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004, CD003048.
26. S Guandalini 2008 Probiotics for children with diarrhea: an update J Clin Gastroenterol 42 Suppl 2 S53 7 10.1097/MCG.0b013e3181674087 18520336
27. CC Chen MS Kong MW Lai, et al. 2010 Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea Pediatr Infect Dis J 29 135 8 10.1097/INF.0b013e3181b530bf 20135748
28. M Hickson AL D'Souza N Muthu, et al. 2007 Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial BMJ 335 80 10.1136/bmj.39231.599815.55 17604300 (Pubitemid 47123282)
29. Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile -associated infection in adults. Cochrane Database Syst Rev 2008, CD004611.
30. LV McFarland 2009 Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections Anaerobe 15 274 80 10.1016/j.anaerobe.2009.09.002 19825425
31. M Miller 2009 The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy Anaerobe 15 281 4 10.1016/j.anaerobe.2009.08.005 19699309
32. C Hammerman A Bin-Nun M Kaplan 2006 Safety of probiotics: comparison of two popular strains BMJ 333 1006 1008 10.1136/bmj.39010.630799.BE 17095783 (Pubitemid 44764349)
33. P Munoz E Bouza M Cuenca-Estrella, et al. 2005 Saccharomyces cerevisiae fungemia: an emerging infectious disease Clin Infect Dis 40 1625 1634 10.1086/429916 15889360 (Pubitemid 40720813)
34. LV McFarland 2010 Systematic review and meta-analysis of Saccharomyces boulardii in adult patients World J Gastroenterol 16 2202 2222 10.3748/wjg.v16.i18.2202 20458757
35. B Eiseman W Silen GS Bascom AJ Kauvar 1958 Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis Surgery 44 854 9 1:STN:280:DyaG1M%2Fit1ShtA%3D%3D 13592638
36. J Aas CE Gessert JS Bakken 2003 Recurrent Clostridium difficile infection: case series involving 18 patients treated with donor stool administered via a nasogastric tube Clin Infect Dis 36 580 585 10.1086/367657 12594638 (Pubitemid 36259562)
37. van Nood E, Speelman P, Kuijper EJ, Keller JJ: Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill 2009, 14.
38. F Rohlke CM Surawicz N Stollman 2010 Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology J Clin Gastroenterol 44 567 70 10.1097/MCG.0b013e3181dadb10 20485184
39. SS Yoon LJ Brandt 2010 Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients J Clin Gastroenterol 44 562 6 10.1097/MCG. 0b013e3181dac035 20463588
40. MM Merrigan SP Sambol S Johnson D Gerding, et al. 2009 New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration Int J Antimicrob Agents 33 Suppl 1 S46 50 1:CAS:528:DC%2BD1MXjsFWksro%3D 10.1016/S0924-8579(09)70017-2 19303570
41. Meader E, Mayer MJ, Gasson MJ, et al: Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 2010, [Epub ahead of print] PubMed PMID: 20816997.
42. L Kyne M Warny A Qamar CP Kelly 2001 Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea Lancet 357 189 193 1:CAS:528:DC%2BD3MXptVyruw%3D%3D 10.1016/S0140-6736(00)03592-3 11213096 (Pubitemid 32108091)
43. BA Leav B Blair M Leney, et al. 2010 Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) Vaccine 28 965 969 1:CAS:528:DC%2BC3cXntlSltg%3D%3D 10.1016/j.vaccine.2009.10. 144 19941990
44. J O'Horo N Safdar 2009 The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review Int J Infect Dis 13 663 7 10.1016/j.ijid.2008.11.012 19186089
45. MS Abougergi A Broor W Lui BG Jaar 2010 Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature J Hosp Med 5 E1 9 10.1002/jhm.542 20063275
46. • Abougergi MS, Kwon JH: Intravenous immunoglobulin for the treatment of Clostridium difficile infection: A Review. Dig Dis Sci. 2010, [Epub ahead of print] PubMed PMID: 20924675. This paper reviews the results of the currently published case reports and clinical trials using IVIg as adjunct therapy of CDI.
47. J Salcedo S Keates C Pothoulakis, et al. 1997 Intravenous immunoglobulin therapy for severe Clostridium difficile infection Gut 41 366 370 1:CAS:528:DyaK2sXms1Shs70%3D 10.1136/gut.41.3.366 9378393
48. IL Beales 2002 Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea Gut 51 456 1:STN:280:DC%2BD38vhvVSrsg%3D%3D 10.1136/gut.51.3.456 12171976
49. MH Wilcox 2004 Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea J Antimicrob Chemother 53 882 884 1:CAS:528:DC%2BD2cXjs1Wqt7w%3D 10.1093/jac/dkh176 15073160 (Pubitemid 38660298)
50. S Pherson CJ Rees, et al. 2006 Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea Dis Colon Rectum 49 640 5 10.1007/s10350-006-0511-8 (Pubitemid 43723812)
51. P Juang SJ Skledar NK Zgheib, et al. 2007 Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea Am J Infect Control 35 131 137 10.1016/j.ajic.2006.06.007 17327194 (Pubitemid 46283599)
52. I Lowy DC Molrine BA Leav, et al. 2010 Treatment with monoclonal antibodies against Clostridium difficile toxins N Engl J Med 362 197 205 1:CAS:528:DC%2BC3cXosFShtw%3D%3D 10.1056/NEJMoa0907635 20089970 This randomized, double-blind, placebo-controlled study showed that infusion of CDA1/CDB1 significantly decreased the recurrence rate of CDI in the study population
53. GJ Babcock TJ Broering HJ Hernandez, et al. 2006 Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters Infect Immun 74 6339 6347 1:CAS:528:DC%2BD28Xht1Khu7zN 10.1128/IAI.00982-06 16966409 (Pubitemid 44657416)
54. BY Lee MJ Popovich Y Tian, et al. 2010 The potential value of Clostridium difficile vaccine: an economic computer simulation model Vaccine 28 5245 53 10.1016/j.vaccine.2010.05.062 20541582
55. Kaslow DC. Emerging concepts for developing vaccines for Clostridium difficile and Methicillin-Resistant Staphylococcus aureus. Annu Rev Med 2011 Jan 27. [Epub ahead of print] PubMed PMID: 20707676.
56. NS Taylor JG Bartlett 1980 Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins J Infect Dis 141 92 7 1:CAS:528: DyaL3cXktlOisr0%3D 7365273
57. K Weiss 2009 Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer Int J Antimicrob Agents 33 4 7 1:CAS:528:DC%2BD1cXhsVKrt7nK 10.1016/j.ijantimicag.2008.07.011 18804351
58. JA Sorg AL Sonenshein 2010 Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid J Bacteriol. 192 4983 90 1:CAS:528:DC%2BC3cXhsFCitbrN 10.1128/JB.00610-10 20675492
59. Giel JL, Sorg JA, Sonenshein AL, Zhu J: Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 2010, :e8740.
60. TJ Louie J Peppe CK Watt, et al. 2006 Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea Clin Infect Dis 43 411 420 1:CAS:528:DC%2BD28XovFWhsrg%3D 10.1086/506349 16838228 (Pubitemid 44157147)
61. PL Hinkson C Dinardo D DiCiero, et al. 2008 Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile Antimicrob Agents Chemother 52 2190 2195 1:CAS:528: DC%2BD1cXmvVait78%3D 10.1128/AAC.00041-08 18391047 (Pubitemid 351758558)
62. SD Baines J Freeman MH Wilcox 2009 Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection Antimicrob Agents Chemother 53 2202 2204 1:CAS:528: DC%2BD1MXlvVGns7Y%3D 10.1128/AAC.01085-08 19223641
63. J Peppe A Porzio DM Davidson 2008 A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial Br J Clin Pharmacol 66 102 9 1:CAS:528: DC%2BD1cXptVKis7s%3D 10.1111/j.1365-2125.2008.03151.x 18341677 (Pubitemid 351822150)
64. SE Noblett M Welfare K Seymour 2009 The role of surgery in Clostridium difficile colitis BMJ 338 b1563 1:STN:280:DC%2BD1Mzis1alsA%3D%3D 10.1136/bmj.b1563 19420031
65. P Butala CM Divino 2010 Surgical aspects of fulminant Clostridium difficile colitis Am J Surg 200 131 5 10.1016/j.amjsurg.2009.07.040 20409527
66. K Gash E Brown A Pullyblank 2010 Emergency subtotal colectomy for fulminant Clostridium difficile colitis-is a surgical solution considered for all patients? Ann R Coll Surg Engl 92 56 60 1:STN:280:DC%2BC3c%2Fht1Cqug%3D%3D 10.1308/003588410X12518836439164 20056063
67. AK Barczak DT Hung 2009 Productive steps toward an antimicrobial targeting virulence Curr Opin Microbiol. 12 490 6 1:CAS:528:DC%2BD1MXht1CmtLfM 10.1016/j.mib.2009.06.012 19631578
68. Z Alvarez E Abel-Santos 2007 Potential use of inhibitors of bacteria spore germination in the prophylactic treatment of anthrax and Clostridium difficile-associated disease Expert Rev Anti Infect Ther 5 783 92 1:CAS:528:DC%2BD2sXht12ru7%2FI 10.1586/14787210.5.5.783 17914913 (Pubitemid 47610942)
69. • Burns DA, Heap JT, Minton NP: Clostridium difficile spore germination: an update. Res Microbiol 2010, [Epub ahead of print] PubMed PMID: 20863888. This paper reviews the current concepts of the process of spore germination by C. difficile.
70. UA Ochsner SJ Bell AL O'Leary, et al. 2009 Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model J Antimicrob Chemother 63 964 71 1:CAS:528:DC%2BD1MXksVaqu7c%3D 10.1093/jac/dkp042 19251726
71. BA Carneiro J Fujii GA Brito, et al. 2006 Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro Infect Immun 74 81 7 1:CAS:528:DC%2BD28XitlKhuw%3D%3D 10.1128/IAI.74.1.81-87.2006 16368960 (Pubitemid 43023061)
72. AA Maciel RB Oriá MB Braga-Neto, et al. 2007 Role of retinol in protecting epithelial cell damage induced by Clostridium difficile toxin A Toxicon 50 1027 40 1:CAS:528:DC%2BD2sXhtlWnsbnL 10.1016/j.toxicon.2007.07.010 17825865 (Pubitemid 350103588)
73. J Ng SA Hirota O Gross, et al. 2010 Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome Gastroenterology 139 542 52 1:CAS:528:DC%2BC3cXpsVGmsrg%3D 10.1053/j.gastro. 2010.04.005 20398664 This study showed that several of the proinflammatory and cytotoxic effects of TcdA and TcdB are mediated via the inflammasome-mediated upregulation of interleukin-1
74. L Franchi T Eigenbrod R Nunoz-Planillo G Nunez 2009 The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis Nat Immunol 10 241 7 1:CAS:528:DC%2BD1MXhvFKjtLo%3D 10.1038/ni.1703 19221555
75. • Abdeen SJ, Swett RJ, Feig AL: Peptide Inhibitors Targeting Clostridium difficile Toxins A and B. ACS Chem Biol 2010, [Epub ahead of print] PubMed PMID: 20863124. This paper used phage display libraries to identify polypeptide inhibitors of the catalytic domain of TcdA in vitro.
76. T Jank MO Ziegler GE Schulz K Aktories 2008 Inhibition of the glucosyltransferase activity of clostridial Rho/Ras-glucosylating toxins by castanospermine FEBS Lett 582 2277 82 1:CAS:528:DC%2BD1cXnt1Ogu7g%3D 10.1016/j.febslet.2008.05.025 18505687
77. SA Hirota K Fines D Traboulsi 2010 Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury Gastroenterology. 139 259 69 1:CAS:528:DC%2BC3cXpsFaitLk%3D 10.1053/j.gastro. 2010.03.045 20347817
78. T Giesemann G Guttenberg K Aktories 2008 Human alpha-defensins inhibit Clostridium difficile toxin B Gastroenterology 134 2049 58 1:CAS:528: DC%2BD1cXosFGltrk%3D 10.1053/j.gastro.2008.03.008 18435932 This study showed that certain human defensins bound with, and partially inactivated, TcdB, but not TcdA (Pubitemid 351783267)